Abstract:<h3>Background</h3><p>α3β1 integrin is a promising cancer biomarker and drug target. We previously identified a 9-amino-acid cyclic peptide LXY30 for detecting α3β1 integrin on the surface of live tumor cells. This study was undertaken to characterize LXY30 in the detection, cellular function, imaging, and targeted delivery of in vitro and in vivo non-small cell lung cancer (NSCLC) models.</p><h3>Methods</h3><p>The whole-cell binding assay was performed by incubating NSCLC cells, extracellular vesicles (EVs), and peripheral blood mononuclear cells (PBMCs) with TentaGel resin beads coated with LXY30. In this study, we defined the nanosize EVs as exosomes, which were characterized by flow cytometry, transmission electron microscopy, dynamic light scattering, and Western blots. The function of LXY30 was determined by modulating the epidermal growth factor receptor (EGFR) signaling pathway by growth inhibition and Western blots. For in vivo biodistribution, mice bearing subcutaneous and intracranial NSCLC xenograft tumors were administrated intraveneously with LXY30-biotin/streptavidin-Cy5.5 complex and then analyzed for in vivo and ex vivo optical imaging and histopathology.</p><h3>Results</h3><p>We showed that LXY30 specifically and sensitively detected α3β1 integrin-expressing NSCLC cells and tumor-derived exosomes. Tumor DNA isolated from LXY30-enriched plasma exosomes might be used to detect driver oncogenic mutations in patients with metastatic NSCLC. LXY30 only enriches tumor cells but not neutrophils, macrophages, or monocytes in the malignant pleural effusion of NSCLC patients for detecting genomic alterations by next-generation sequencing. LXY30 detected increased α3β1 integrin expression on the <em>EGFR</em>-mutant NSCLC cells with acquired resistance to erlotinib compared to parental erlotinib-sensitive <em>EGFR</em>-mutant NSCLC cells. We further showed that LXY30 modulated the EGFR signaling pathway independently from another peptide ligand LXW64 targeting αvβ3 integrin in erlotinib-resistant, <em>EGFR</em>-mutant H1975 cells. Analysis of The Cancer Genome Atlas (TCGA) revealed high α3 integrin expression was associated with poor prognosis in lung squamous cell carcinoma. LXY30-biotin/streptavidin-Cy5.5 complex had higher uptakes in the subcutaneous and intracranial xenografts of various α3β1 integrin-expressing lung adenocarcinoma and patient-derived lung squamous cell carcinoma xenografts while sparing the surrounding normal tissues.</p><h3>Conclusion</h3><p>LXY30 is a promising peptide for the cancer diagnosis and in vivo targeted delivery of imaging agents and cancer drugs in NSCLC, independent of histology and tumor genotype.</p>

[Molecular Cloning and Expression of Anti-Tumor Adhesion Peptide (Beta3)].

Enhanced Membrane-tethered Mucin 3 (MUC3) Expression by a Tetrameric Branched Peptide with a Conserved TFLK Motif Inhibits Bacteria Adherence*

Cloning and Expression of the Cdna Encoding Human Tissue Inhibitor of Metalloproteinase-3 and Its Inhibition on Angiogenesis

Characterization of a Novel Recombinant Calcium-Binding Protein from Arca Subcrenata and Its Anti-Hepatoma Activities in Vitro and in Vivo.

Methyl-CpG-binding Domain 3 Inhibits Epithelial–mesenchymal Transition in Pancreatic Cancer Cells Via TGF-β/Smad Signalling

Effect of the Pegylation of Trimeric Β Peptide on It's Anti-metastasis Activity

A Novel Recombinant Fusion Protein with Soluble PD-1 and TIM-3 Domains Effectively Binds to Cancer Cells

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

[Monoclonal Antibody Against G3BP: Preparation, Characterization and Its Application in Analysis of Human Tumors].

Betaig-h3 interacts with alpha3beta1 integrin to promote adhesion and migration of human hepatoma cells

Inhibitory Effects of Synthetic Β Peptide on Invasion and Metastasis of Liver Cancer

Screening a DNA Aptamer Specifically Targeting Integrin β3 and Partially Inhibiting Tumor Cell Migration

Design and characterization of a novel tumor‐homing cell‐penetrating peptide for drug delivery in TGFBR3 high‐expressing tumors

High-affinity peptide ligand LXY30 for targeting α3β1 integrin in non-small cell lung cancer

Albumin Fusion at the N-Terminus or C-Terminus of HM-3 Leads to Improved Pharmacokinetics and Bioactivities

Purification and Characterization of Rgd Tumor-Homing Peptide Conjugated Human Tumor Necrosis Factor Alpha Over-Expressed in Escherichia Coli

Molecular Cloning of a Tumor-Associated Antigen Recognized by Monoclonal Antibody 3H11

Novel Linear Peptides with High Affinity to Αvβ3 Integrin for Precise Tumor Identification.

Integrin Alpha(v)beta(3)-Targeted Cancer Therapy.

Design, Activity Determination and 99mtc Labeling of Cyclic RGD Dimer for Targeting Integrin Αvβ3

Monoclonal Antibodies Against Human Tumor Metastasis Suppressor Gene-1 (TMSG-1): Preparation, Characterization, and Application.